Colorectal cancer: Recent advances in management and treatment

Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration for the treatment of colorectal cancer

Trade name	Generic name	Strategy	Date of FDA approval	Type of cancer	Local/metastatic
Jemperli	Dostarlimab	PD-1 inhibitor	January 2023	dMMR/MSI-H	Local
Yervoy	Ipilimumab	CTLA-4 inhibitor	July 2018	dMMR/MSI-H	Metastatic
Opdivo	Nivolumab	PD-1 inhibitor	July 2017	dMMR/MSI-H	Metastatic
Keytruda	Pembrolizumab	PD-1 inhibitor	June 2020 (first-line treatment)	dMMR/MSI-H	Metastatic
			May 2017 (second-line treatment)

CTLA-4: Cytotoxic T-lymphocyte associated protein 4; dMMR: Deficient mismatch repair; FDA: Food and Drug Administration; MSI-H: High microsatellite instability; PD-1: Programmed death 1.